DiaMedica Therapeutics (DMAC) Debt Ratio (2017)
DiaMedica Therapeutics' (DMAC) quarterly Debt Ratio came in at 0.05 in Q4 2017.
Powered by 
Analysis
DiaMedica Therapeutics (DMAC) Debt Ratio (2017) Analysis & Trends
DiaMedica Therapeutics (DMAC) has reported Debt Ratio for 1 consecutive years, with 0.05 the latest figure, recorded in Q4 2017.
- For the quarter ending Q4 2017, Debt Ratio changed N/A year-over-year to 0.05; the trailing twelve-month figure through Dec 2017 stood at 0.05 (changed N/A YoY), and the FY2017 full-year result was 0.05, changed N/A from the prior year.
- Debt Ratio held at 0.05 in Q4 2017 per DMAC's latest filing.
- Across five years, Debt Ratio topped out at 0.05 in Q4 2017 and bottomed at 0.05 in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.59 Bn | 193.60 Bn | 7.24 Bn | 0.66 |
| 2 | Gilead Sciences | 178.73 Bn | 175.55 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 131.17 Bn | 123.32 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.73 Bn | 73.73 Bn | 3.93 Bn | 0.05 |
| 5 | Argenx Se | 61.01 Bn | 55.82 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.40 Bn | 48.27 Bn | 52.00 Mn | 0.05 |
| 7 | Alnylam Pharmaceuticals | 33.49 Bn | 30.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.64 Bn | 30.35 Bn | 1.96 Bn | 0.25 |
| 9 | Roivant Sciences | 29.66 Bn | 29.66 Bn | 1.16 Mn | - |
| 10 | DiaMedica Therapeutics | 351.39 Mn | 351.39 Mn | - | - |